Overview Financials News + Filings Key Docs Charts Transactions Holdings Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Director departure
Appointed director
Inv. presentation
|
|
Sorrento Therapeutics, Inc. (SRNE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 10/05/2023 |
SC 13G/A
| Sorrento Therapeutics, Inc. reports a 2.6% stake in CELULARITY INC. |
| 10/05/2023 |
4
| Sorrento Therapeutics, Inc. (10% Owner) has filed a Form 4 on Celularity Inc|
Txns:
| Sold 9,064,539 shares
@ $0
Sold 6,307,158 shares
@ $0 |
|
| 09/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disp...|
Docs:
|
"SCILEX HOLDING COMPANY AND SORRENTO THERAPEUTICS, INC. STOCK PURCHASE AGREEMENT",
"WHEREAS",
"ASSIGNMENT, ASSUMPTION AND RELEASE AGREEMENT",
"UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION On September 21, 2023, Sorrento Therapeutics, Inc. entered into a stock purchase agreement with Scilex Holding Company whereby Scilex acquired all of the shares of Scilex common stock owned by Sorrento , all of the shares of Series A preferred stock of Scilex owned by Sorrento and all of the warrants for the purchase of shares of Scilex common stock owned by Sorrento for aggregate consideration consisting of: $110 million ); the assumption by Scilex of certain obligations of Sorrento for legal fees and expenses in the amount of approximately $12.25 million; and a credit bid of approximately $23 million, representing all amounts owed to Scilex under the Company’ s non-amortizing super-priority junior secured term loan facility...",
"Sorrento Therapeutics, Inc. Announces the Consummation of the Previously Announced Sale of Substantially All of the Common Shares, Preferred Shares and Warrants that Sorrento Held in Scilex Holding Company SAN DIEGO, CA. September 22, 2023 /Newswire/ -- Sorrento Therapeutics, Inc. , a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, announced the consummation on September 21, 2023, of the previously announced sale to Scilex Holding Company of certain securities that Sorrento held in Scilex. Pursuant to that certain Stock Purchase Agreement entered into on September 21, 2023, between Scilex and Sorrento, Scilex, through its wholly-owned subsidiary, acquired all of the shares of Scilex common stock o..." |
|
| 09/26/2023 |
SC 13D/A
| Sorrento Therapeutics, Inc. reports a 1.3% stake in Scilex Holding Company |
| 08/21/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UST Form 11-MOR 2 Debtor's Name SORRENTO THERAPEUTICS, INC. Case No. 23-90085 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $35,876,091 b. Total receipts $15,041,433 $77,652,663 c. Total disbursements $21,386,073 $60,615,327 d. Cash balance end of month $29,531,451 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation $21,386,073 $60,615,327 Part 2: Asset and Liability Status Current Month a. Accounts receivable $64,000 b. Accounts receivable over 90 days outstanding $64,000 c. Inventory ) $0 d Total current assets $44,233,000 e. Total assets $704,140,000 f. Postpetition payables $168,333,000 g. Postpetition payables past due $4,647,000 h. Postpetition taxes payable...",
"UST Form 11-MOR 2 Debtor's Name SCINTILLA PHARMACEUTICALS, INC. Case No. 23-90084 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $60,000 b. Total receipts $0 $0 c. Total disbursements $0 $0 d. Cash balance end of month $60,000 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation $0 $0 Part 2: Asset and Liability Status Current Month a. Accounts receivable $0 b. Accounts receivable over 90 days outstanding $0 c. Inventory ) $0 d Total current assets $60,000 e. Total assets $60,000 f. Postpetition payables $0 g. Postpetition payables past due $0 h. Postpetition taxes payable $0 i. Postpetition taxes past due $0 j. Total postpetition debt $0 k. Prepetition secured debt..." |
|
| 08/10/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"STOCK PURCHASE AGREEMENT",
"Amendment Agreement to Stock Purchase Agreement, between Sorrento Therapeutics, Inc. amd Oramed Pharmaceutircals Inc",
"SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION",
"Stalking Horse Stock Purchase Term Sheet",
"Sorrento Therapeutics, Inc. Announces Auction for Sale of Scilex Securities and Bankruptcy Court Approval of Stalking Horse Bid SAN DIEGO, – Sorrento Therapeutics, Inc. , a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order approving a $105 million “stalking horse” bid for substantially all of the Debtors’ common stock, preferred stock, and warrants in Scilex Holding Company to Oramed Pharmaceuticals, Inc. . The stalking horse agreement with Oramed is subject to an auction and the submission of higher or otherwise better offers. Any parties interested in ..." |
|
| 08/07/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 08/01/2023 |
8-K
| Quarterly results |
| 07/18/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 07/13/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"UST Form 11-MOR 2 Debtor's Name SORRENTO THERAPEUTICS, INC. Case No. 23-90085 Part 1: Cash Receipts and Disbursements Current Month Cumulative a. Cash balance beginning of month $34,454,067 b. Total receipts $12,156,833 $62,611,230 c. Total disbursements $10,734,809 $39,229,254 d. Cash balance end of month $35,876,091 e. Disbursements made by third party for the benefit of the estate $0 $0 f. Total disbursements for quarterly fee calculation $10,734,809 $39,229,254 Part 2: Asset and Liability Status Current Month a. Accounts receivable $70,128 b. Accounts receivable over 90 days outstanding $70,128 c. Inventory ) Book Market Other $0 d Total current assets $53,382,403 e. Total assets $742,166,196 f. Postpetition payables $163,734,798 g. Postpetition payables past due $3,708,059 h. Postpeti...",
"UST Form 11-MOR 1 UNITED STATES BANKRUPTCY COURT SOUTHERN DISTRICT OF TEXAS HOUSTON DIVISION In Re. SCINTILLA PHARMACEUTICALS, INC. Debtor § § § § Case No. 23-90084 Lead Case No. 23-90085 Jointly Administered Monthly Operating Report Chapter 11 Reporting Period Ended: 05/31/2023 Petition Date: 02/13/2023 Months Pending: 4 Industry Classification: 3254 Reporting Method: Accrual Basis Cash Basis Debtor's Full-Time Employees : 0 Debtor's Full-Time Employees : 0 Supporting Documentation : Statement of cash receipts and disbursements Balance sheet containing the summary and detail of the assets, liabilities and equity or deficit Statement of operations Accounts receivable aging Postpetition liabilities aging Statement of capital assets Schedule of payments to professionals S..." |
|
| 07/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"SORRENTO THERAPEUTICS, INC. SCINTILLA PHARMACEUTICALS, INC. Debtor-in-Possession Term Loan Facility Summary of Terms and Conditions This term sheet sets forth a summary of the terms and conditions with respect to the DIP Facility from and after, and subject to, the entry of the Junior Interim Order . This Term Sheet shall be a binding agreement from and after, and subject to, the entry of the Junior Interim Order with respect to the DIP Loans but does not purport to summarize all of the terms, conditions, representations and other provisions with respect to the DIP Facility, which will be set forth in the DIP Documents . The obligation of the DIP Lender to provide financing pursuant to this Term Sheet is conditioned upon the execution and delivery of signature pages to this Term Sheet by e...",
"RECITALS" |
|
| 05/15/2023 |
8-K
| Regulation FD Disclosure, Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Sorrento Therapeutics, Inc.’ s Bankruptcy Court Orders Brokerage Firms to Credit Dividended Scilex Stock to Customers’ Accounts and Sorrento Advises Holders of Dividended Scilex Stock to Contact Brokerage Firms to Deliver the Stock to Individual Accounts SAN DIEGO, – Sorrento Therapeutics, Inc. , a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas has entered an order compelling certain brokerage firms to credit all shares of common stock of Scilex Holding Company that Sorrento distributed to its stockholders on or around January 19, 2023 to their customers’ accounts. In..." |
|
| 05/12/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 05/02/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 03/30/2023 |
8-K
| Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits Inte...|
Docs:
|
"SENIOR SECURED, SUPER-PRIORITY DEBTOR-IN-POSSESSION",
"Sorrento Therapeutics, Inc. Receives Final Court Approval for $75 Million Debtor-In-Possession Financing SAN DIEGO, – Sorrento Therapeutics, Inc. , a biopharmaceutical company dedicated to the development of life-saving therapeutics to treat cancer, intractable pain, and infectious disease, today announced that the U.S. Bankruptcy Court for the Southern District of Texas granted final approval of Sorrento’ s $75 million debtor-in-possession financing from JMB Capital Partners, in connection with Sorrento’ s chapter 11 case that was filed on February 13, 2023. This follows the Court’ s interim approval of the DIP financing, granted on February 21, 2023 with respect to $30 million of the DIP financing. Today’ s final approval provides Sorrento with an additional $45 million of liquidity so t..." |
|
| 03/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 03/10/2023 |
SC 13G/A
| STATE STREET CORP reports a 0% stake in EXIT FILING SORRENTO THERAPEUTICS INC |
| 03/08/2023 |
SC 13G/A
| BlackRock Inc. reports a 0% stake in SORRENTO THERAPEUTICS INC |
| 03/03/2023 |
SC 13D/A
| Sorrento Therapeutics, Inc. reports a 44.2% stake in Scilex Holding Company |
| 02/21/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
8-K
| Quarterly results |
| 02/09/2023 |
SC 13G/A
| STATE STREET CORP reports a 10.7% stake in AMEMDED FILING SORRENTO THERAPEUTICS INC |
| 02/09/2023 |
SC 13G/A
| VANGUARD GROUP INC reports a 6.3% stake in Sorrento Therapeutics Inc. |
| 02/06/2023 |
5
| Janda Kim (Director) has filed a Form 5 on Sorrento Therapeutics, Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/02/2023 |
8-K
| Quarterly results |
| 01/30/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data|
Docs:
|
"FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC. Q: What is the dividend of Scilex Common Stock? A: On December 30, 2022, Sorrento Therapeutics, Inc. announced that its board of directors declared a stock dividend consisting of an aggregate of 76,000,000 shares of common stock of Scilex Holding Company held by Sorrento to record holders of: · Sorrento’ s common stock as of the close of business on the Record Date, and · certain warrants to purchase Sorrento common stock . The Dividend would be apportioned on a pro rata basis among such holders in accordance with each holder’ s ownership percentage of Sorrento common stock as of the Record Date as set forth in the records of Sorrento’ s transfer agent and S...",
"FREQUENTLY ASKED QUESTIONS REGARDING THE DIVIDEND OF SCILEX HOLDING COMPANY COMMON STOCK BY SORRENTO THERAPEUTICS, INC. Q: What is the dividend of Scilex Common Stock? A: On December 30, 2022, Sorrento Therapeutics, Inc. announced that its board of directors declared a stock dividend consisting of an aggregate of 76,000,000 shares of common stock of Scilex Holding Company held by Sorrento to record holders of: · Sorrento’ s common stock as of the close of business on the Record Date, and · certain warrants to purchase Sorrento common stock ." |
|
| 01/23/2023 |
SC 13D/A
| Sorrento Therapeutics, Inc. reports a 45.5% stake in Scilex Holding Company |
| 01/23/2023 |
4
| Sorrento Therapeutics, Inc. (10% Owner) has filed a Form 4 on Scilex Holding Co|
Txns:
| Disposed of 73,740,795 shares
@ $0 |
|
|
|
|